CytoMed Therapeutics Limited (GDTC)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Chee Kong Choo
|
Executive Chairman | 38.14k | -- | 1958 |
|
Dr. Jieming Zeng M.D., Ph.D.
|
Chief Scientific & Medical Officer and Director | 102.04k | -- | 1974 |
|
Ms. Yvonne Goh
|
Chief Financial Officer | -- | -- | 1990 |
|
Dr. Tien Wee Luk M.D.
|
Chief Clinical Officer | -- | -- | 1984 |
|
Ms. Yoong Ying Tan
|
Chief Corporate Officer | -- | -- | 1989 |
CytoMed Therapeutics Limited
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 42
Description
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
